Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Negative and Cognitive Symptoms of Schizophrenia

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...

Cognitive Therapy

Cognitive Therapy

Cognitive therapy, pioneered by Aaron T. Beck in the 1960s, is a structured approach to addressing psychological distress by focusing on the influence of thoughts on emotions and behaviors. All cognitive therapies involve the basic assumption that human beings have control over their feelings, and that how individuals feel about something depends on how they think about it. Unlike psychoanalytic methods that delve into unconscious processes or humanistic approaches emphasizing...

Guidelines for Writing Outcome

Guidelines for Writing Outcome

When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care evaluation by...

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Spontaneous spinal epidural hematoma in the setting of Evans syndrome: a case report and literature review.

Journal of spine surgery (Hong Kong)·2026

Same author

Predictors of long-term care admission in a rural and remote memory clinic.

Journal of Alzheimer's disease : JAD·2026

Same author

Does anticholinergic medication use on presentation to a rural memory clinic predict cognitive or functional decline over one year?

Journal of Alzheimer's disease : JAD·2026

Same author

Low utility of pre-operative cardiology referrals in adolescent idiopathic scoliosis using a cutoff of Cobb > 70 degrees.

Spine deformity·2025

Same author

Do Education and Premorbid Intelligence Predict Cognitive Decline Over 1 Year in Rural Patients with Dementia?

Alzheimer disease and associated disorders·2025

Same author

Practice Pattern Preferences Among Pediatric Orthopaedic Surgeons in North America for the Treatment of Femoral Shaft Fractures.

Journal of the Pediatric Orthopaedic Society of North America·2025

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Target symptoms and outcome measures: cognition.

¹Division of Neurology, University of Saskatchewan, Royal University Hospital, Saskatoon, Saskatchewan, Canada.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques

|May 2, 2007

Summary

The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) is widely used but may not suit all dementia types. New cognitive measures are needed for non-Alzheimer dementias to improve clinical trial accuracy.

More Related Videos

Development of a Virtual Reality Assessment of Everyday Living Skills

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Related Experiment Videos

Last Updated: Jul 15, 2026

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Development of a Virtual Reality Assessment of Everyday Living Skills

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Area of Science:

Neuroscience
Clinical Trials
Cognitive Assessment

Background:

The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) is the standard cognitive measure in dementia research.
However, it has limitations, not assessing key cognitive domains like attention or executive function.
Its suitability for non-Alzheimer dementias is questionable.

Purpose of the Study:

To evaluate the adequacy of the ADAS-Cog in various dementia trials.
To identify limitations of current cognitive measures for non-Alzheimer dementias.
To highlight the need for tailored cognitive assessments.

Main Methods:

Review of the ADAS-Cog's application in clinical trials for Alzheimer's disease (AD), mild cognitive impairment (MCI), vascular dementia, mixed dementia, dementia with Lewy bodies, and frontotemporal dementia (FTD).
Discussion of alternative assessments for specific cognitive domains and dementia types, including aphasia batteries and executive function tests.
Consideration of tools for advanced dementia and patient stratification.

Main Results:

The ADAS-Cog effectively differentiates between AD, MCI, and healthy controls.
Its use in trials for vascular dementia, mixed dementia, and dementia with Lewy bodies has been documented.
The ADAS-Cog's adequacy is uncertain for frontotemporal dementia, necessitating complementary assessments like the Frontal Assessment Battery or Executive Interview.
The Severe Impairment Battery is used for advanced dementia.
The Mini-Mental State Exam and Modified Mini-Mental State Examination aid in trial stratification.

Conclusions:

The ADAS-Cog, while valuable for AD, may not be optimal for all dementia subtypes.
Specialized cognitive measures are required for non-Alzheimer dementias to ensure accurate assessment and trial outcomes.
Further development of tailored cognitive tools is crucial for advancing dementia research.